ALNYLAM PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$56.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$56.60M.
- ALNYLAM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$28.50M, a 104.57% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $623.00M, a 61.99% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $384.60M, a 16.26% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$56.60M 10-K · filed 2026-02-12 | |
| 2024-12-31 | -$28.50M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $623.00M 10-K · filed 2026-02-12 | $623.80M 10-K · filed 2024-02-15 |
| 2022-12-31 | $384.60M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $459.30M 10-K · filed 2024-02-15 | |
| 2020-12-31 | $303.70M 10-K · filed 2023-02-23 | |
| 2019-12-31 | $185.90M 10-K · filed 2022-02-10 | |
| 2018-12-31 | $171.80M 10-K · filed 2021-02-11 | |
| 2017-12-31 | $112.90M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $177.90M 10-K · filed 2019-02-14 | |
| 2015-12-31 | $129.10M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $46.00M 10-K · filed 2017-02-15 | |
| 2013-12-31 | $29.70M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $38.30M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $23.00M 10-K · filed 2014-02-20 | |
| 2010-12-31 | $15.20M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |